Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

1. Metabolic Syndrome - Pipeline Review, H1 2014
This report provides comprehensive information on the therapeutic development for Metabolic Syndrome, complete with comparative analysis at various stages,
therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured
news and press releases. It also reviews key players involved in the therapeutic development for Metabolic Syndrome and special features on late-stage and
discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built
using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and
featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the
latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that
the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by
identifying new targets and MOAs to produce first-in-class and best-in-class products.
Scope
The report provides a snapshot of the global therapeutic landscape of Metabolic Syndrome The report reviews key pipeline products under drug profile section
which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players
involved in the therapeutics development for Metabolic Syndrome and enlists all their major and minor projects The report summarizes all the dormant and
discontinued pipeline projects A review of the Metabolic Syndrome products under development by companies and universities/research institutes based on
information derived from company and industry-specific sources Pipeline products coverage based on various stages of development ranging from
pre-registration till discovery and undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Metabolic
Syndrome pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players
with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the
focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Metabolic Syndrome Plan mergers
and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding
Metabolic Syndrome pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective
partners with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove them from pipeline
table Of Contents
table Of Contents 2
list Of Tables 6
list Of Figures 7
introduction 8
global Markets Direct Report Coverage 8
metabolic Syndrome Overview 9
therapeutics Development 10
pipeline Products For Metabolic Syndrome Overview 10
pipeline Products For Metabolic Syndrome Comparative Analysis 11
metabolic Syndrome Therapeutics Under Development By Companies 12
metabolic Syndrome Therapeutics Under Investigation By Universities/institutes 15
metabolic Syndrome Pipeline Products Glance 17
late Stage Products 17
clinical Stage Products 18
early Stage Products 19
unknown Stage Products 20
metabolic Syndrome Products Under Development By Companies 21
metabolic Syndrome Products Under Investigation By Universities/institutes 22
metabolic Syndrome Companies Involved In Therapeutics Development 23
dainippon Sumitomo Pharma Co., Ltd. 23
ildong Pharmaceutical Co., Ltd. 24
chipscreen Biosciences Ltd 25
abeille Pharmaceuticals, Inc. 26
cortendo Invest Ab 27
spherix Incorporated 28
ache Laboratorios Farmaceuticos S/a 29
indus Biotech Private Limited 30
cardax Pharmaceuticals, Inc. 31
vivacell Biotechnology Espana S.l. 32
poxel Sa 33
shanghai Pharmaceuticals Holding Co Ltd 34
lead Discovery Center Gmbh 35
Metabolic Syndrome - Pipeline Review, H1 2014

2. mi.to. Technology S.r.l. 36
metabolic Syndrome Therapeutics Assessment 37
assessment By Monotherapy Products 37
assessment By Target 38
assessment By Mechanism Of Action 41
assessment By Route Of Administration 44
assessment By Molecule Type 46
drug Profiles 48
cs-038 - Drug Profile 48
product Description 48
mechanism Of Action 48
r&d Progress 48
ach-09 - Drug Profile 50
product Description 50
mechanism Of Action 50
r&d Progress 50
mbx-8025 - Drug Profile 51
product Description 51
mechanism Of Action 51
r&d Progress 51
chloroquine - Drug Profile 53
product Description 53
mechanism Of Action 53
r&d Progress 53
eplerenone - Drug Profile 54
product Description 54
mechanism Of Action 54
r&d Progress 54
spx-10624258 - Drug Profile 55
product Description 55
mechanism Of Action 55
r&d Progress 55
mb-12066 - Drug Profile 56
product Description 56
mechanism Of Action 56
r&d Progress 56
ab-3001 - Drug Profile 57
product Description 57
mechanism Of Action 57
r&d Progress 57
cdx-085 - Drug Profile 58
product Description 58
mechanism Of Action 58
r&d Progress 58
cde-001 - Drug Profile 60
product Description 60
mechanism Of Action 60
r&d Progress 60
gq-16 - Drug Profile 61
product Description 61
mechanism Of Action 61
r&d Progress 61
next Generation Cortisol Inhibitor - Drug Profile 62
product Description 62
mechanism Of Action 62
r&d Progress 62
nd-630 - Drug Profile 63
product Description 63
mechanism Of Action 63
r&d Progress 63
drug Targeting Ampd2 - Drug Profile 64
product Description 64
mechanism Of Action 64
r&d Progress 64
kh-064 - Drug Profile 65
product Description 65
mechanism Of Action 65
r&d Progress 65
Metabolic Syndrome - Pipeline Review, H1 2014

3. metabolic Syndrome Program - Drug Profile 67
product Description 67
mechanism Of Action 67
r&d Progress 67
metabolic Syndrome Program - Drug Profile 68
product Description 68
mechanism Of Action 68
r&d Progress 68
small Molecules To Inversely Agonize Beta3-adrenoreceptor For Cachexia, Metabolic Syndrome And Heart Failure - Drug Profile 69
product Description 69
mechanism Of Action 69
r&d Progress 69
small Molecules For Inflammatory Diseases - Drug Profile 70
product Description 70
mechanism Of Action 70
r&d Progress 70
myonectin - Drug Profile 71
product Description 71
mechanism Of Action 71
r&d Progress 71
id-2244 - Drug Profile 72
product Description 72
mechanism Of Action 72
r&d Progress 72
zln-024 - Drug Profile 73
product Description 73
mechanism Of Action 73
r&d Progress 73
c-24 - Drug Profile 74
product Description 74
mechanism Of Action 74
r&d Progress 74
drug Targeting Farnesoid X Receptor - Drug Profile 75
product Description 75
mechanism Of Action 75
r&d Progress 75
apoptosis Inhibitor Of Macrophages - Drug Profile 76
product Description 76
mechanism Of Action 76
r&d Progress 76
small Molecule For Cardiovascular And Metabolic Disorders - Drug Profile 77
product Description 77
mechanism Of Action 77
r&d Progress 77
small Molecules To Inhibit Parp For Immunology, Oncology, Cardiovascular And Metabolic Disorders - Drug Profile 78
product Description 78
mechanism Of Action 78
r&d Progress 78
drugs Targeting Acetyl-coa Carboxylase - Drug Profile 79
product Description 79
mechanism Of Action 79
r&d Progress 79
11 Beta Hydroxysteroid Dehydrogenase 1 Inhibitors - Drug Profile 80
product Description 80
mechanism Of Action 80
r&d Progress 80
drug Targeting Sirt - Drug Profile 81
product Description 81
mechanism Of Action 81
r&d Progress 81
oligonucleotide To Inhibit Irak-3 For Cardiovascular And Metabolic Disorders - Drug Profile 82
product Description 82
mechanism Of Action 82
r&d Progress 82
tgr-5 Agonist Program - Drug Profile 83
product Description 83
mechanism Of Action 83
r&d Progress 83
Metabolic Syndrome - Pipeline Review, H1 2014

4. indus-810 - Drug Profile 84
product Description 84
mechanism Of Action 84
r&d Progress 84
metabolic Syndrome Recent Pipeline Updates 85
metabolic Syndrome Dormant Projects 87
metabolic Syndrome Discontinued Products 88
metabolic Syndrome Product Development Milestones 89
featured News & Press Releases 89
nov 11, 2013: Micardis Crosses 50 Million Patient-years Of Experience On 15th Anniversary 89
aug 28, 2012: Cardax Pharma To Obtain Chinese Patent Protection For Lead Compound Cdx-085 89
apr 26, 2012: Miragen Announces Publication Of Data On Mirg-9103 In Journal Cell 90
feb 27, 2012: Kadmon Announces Dosing Of First Patient In Phase I Study Of Kd025 91
sep 12, 2011: Cardiotrophin 1 Shows Promising Results For Treatment Of Obesity And Metabolic Syndrome 91
jun 07, 2008: Orexigen Therapeutics Announces That Contrave May Reverse The Incidence Of Metabolic Syndrome 92
appendix 94
methodology 94
coverage 94
secondary Research 94
primary Research 94
expert Panel Validation 94
contact Us 95
disclaimer 95
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Metabolic Syndrome - Pipeline Review, H1 2014